EICHORCondition: Neuroblastoma · Relapsed Neuroblastoma · Refractory Neuroblastoma · Sponsor: Clarity Pharmaceuticals Ltd
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Cincinnati Children's Hospital Medical Centre | Cincinnati, Ohio, United States | — |
| Medical University of South Carolina | Charleston, South Carolina, United States | — |
| University of Texas Southwestern Medical Centre | Dallas, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| University of Wisconsin | Madison, Wisconsin, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04023331